305 related articles for article (PubMed ID: 26141862)
1. Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.
Hultberg A; Morello V; Huyghe L; De Jonge N; Blanchetot C; Hanssens V; De Boeck G; Silence K; Festjens E; Heukers R; Roux B; Lamballe F; Ginestier C; Charafe-Jauffret E; Maina F; Brouckaert P; Saunders M; Thibault A; Dreier T; de Haard H; Michieli P
Cancer Res; 2015 Aug; 75(16):3373-83. PubMed ID: 26141862
[TBL] [Abstract][Full Text] [Related]
2. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
Yu Y; Chen Y; Ding G; Wang M; Wu H; Xu L; Rui X; Zhang Z
Biochem Biophys Res Commun; 2015 Aug; 464(1):154-60. PubMed ID: 26093299
[TBL] [Abstract][Full Text] [Related]
3. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
[TBL] [Abstract][Full Text] [Related]
4. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody.
Pacchiana G; Chiriaco C; Stella MC; Petronzelli F; De Santis R; Galluzzo M; Carminati P; Comoglio PM; Michieli P; Vigna E
J Biol Chem; 2010 Nov; 285(46):36149-57. PubMed ID: 20833723
[TBL] [Abstract][Full Text] [Related]
5. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
Chen L; Li C; Zhu Y
Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
[TBL] [Abstract][Full Text] [Related]
6. Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumab.
Mai E; Zheng Z; Chen Y; Peng J; Severin C; Filvaroff E; Romero M; Mallet W; Kaur S; Gelzleichter T; Nijem I; Merchant M; Young JC
Mol Cancer Ther; 2014 Feb; 13(2):540-52. PubMed ID: 24258345
[TBL] [Abstract][Full Text] [Related]
7. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.
Liu L; Zeng W; Wortinger MA; Yan SB; Cornwell P; Peek VL; Stephens JR; Tetreault JW; Xia J; Manro JR; Credille KM; Ballard DW; Brown-Augsburger P; Wacheck V; Chow CK; Huang L; Wang Y; Denning I; Davies J; Tang Y; Vaillancourt P; Lu J
Clin Cancer Res; 2014 Dec; 20(23):6059-70. PubMed ID: 25231402
[TBL] [Abstract][Full Text] [Related]
8. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
Kim KJ; Wang L; Su YC; Gillespie GY; Salhotra A; Lal B; Laterra J
Clin Cancer Res; 2006 Feb; 12(4):1292-8. PubMed ID: 16489086
[TBL] [Abstract][Full Text] [Related]
9. MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.
Casaletto JB; Geddie ML; Abu-Yousif AO; Masson K; Fulgham A; Boudot A; Maiwald T; Kearns JD; Kohli N; Su S; Razlog M; Raue A; Kalra A; Håkansson M; Logan DT; Welin M; Chattopadhyay S; Harms BD; Nielsen UB; Schoeberl B; Lugovskoy AA; MacBeath G
Proc Natl Acad Sci U S A; 2019 Apr; 116(15):7533-7542. PubMed ID: 30898885
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
[TBL] [Abstract][Full Text] [Related]
11. Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.
Goodwin CR; Lal B; Zhou X; Ho S; Xia S; Taeger A; Murray J; Laterra J
Cancer Res; 2010 Apr; 70(7):2932-41. PubMed ID: 20233866
[TBL] [Abstract][Full Text] [Related]
12. Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models.
Coxon A; Rex K; Meyer S; Sun J; Sun J; Chen Q; Radinsky R; Kendall R; Burgess TL
Mol Cancer Ther; 2009 May; 8(5):1119-25. PubMed ID: 19435874
[TBL] [Abstract][Full Text] [Related]
13. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.
Merchant M; Ma X; Maun HR; Zheng Z; Peng J; Romero M; Huang A; Yang NY; Nishimura M; Greve J; Santell L; Zhang YW; Su Y; Kaufman DW; Billeci KL; Mai E; Moffat B; Lim A; Duenas ET; Phillips HS; Xiang H; Young JC; Vande Woude GF; Dennis MS; Reilly DE; Schwall RH; Starovasnik MA; Lazarus RA; Yansura DG
Proc Natl Acad Sci U S A; 2013 Aug; 110(32):E2987-96. PubMed ID: 23882082
[TBL] [Abstract][Full Text] [Related]
14. Filamin a mediates HGF/c-MET signaling in tumor cell migration.
Zhou AX; Toylu A; Nallapalli RK; Nilsson G; Atabey N; Heldin CH; Borén J; Bergo MO; Akyürek LM
Int J Cancer; 2011 Feb; 128(4):839-46. PubMed ID: 20473907
[TBL] [Abstract][Full Text] [Related]
15. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
16. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.
Luraghi P; Reato G; Cipriano E; Sassi F; Orzan F; Bigatto V; De Bacco F; Menietti E; Han M; Rideout WM; Perera T; Bertotti A; Trusolino L; Comoglio PM; Boccaccio C
Cancer Res; 2014 Mar; 74(6):1857-69. PubMed ID: 24448239
[TBL] [Abstract][Full Text] [Related]
17. Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways.
Previdi S; Maroni P; Matteucci E; Broggini M; Bendinelli P; Desiderio MA
Eur J Cancer; 2010 Jun; 46(9):1679-91. PubMed ID: 20350802
[TBL] [Abstract][Full Text] [Related]
18. The Sema domain of Met is necessary for receptor dimerization and activation.
Kong-Beltran M; Stamos J; Wickramasinghe D
Cancer Cell; 2004 Jul; 6(1):75-84. PubMed ID: 15261143
[TBL] [Abstract][Full Text] [Related]
19. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation.
Lal B; Xia S; Abounader R; Laterra J
Clin Cancer Res; 2005 Jun; 11(12):4479-86. PubMed ID: 15958633
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
